Wei, Yongyue
Liang, Junya
Zhang, Ruyang
Guo, Yichen
Shen, Sipeng
Su, Li
Lin, Xihong
Moran, Sebastian
Helland, Åslaug
Bjaanæs, Maria M.
Karlsson, Anna
Planck, Maria
Esteller, Manel
Fleischer, Thomas
Staaf, Johan
Zhao, Yang
Chen, Feng
Christiani, David C.
Funding for this research was provided by:
National Natural Science Foundation of China (81530088, 81473070, 81402764, 81373102, 81402763)
State's Key Project of Research and Development Program (2016YFE0204900)
A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions
National Institute of Health (CA092824, CA209414)
Article History
Received: 22 January 2018
Accepted: 16 March 2018
First Online: 2 April 2018
Ethics approval and consent to participate
: The Harvard study protocol was approved by the Institutional Review Boards at Harvard School of Public Health and MGH. The Spain study was approved by the Bellvitge Biomedical Research Institute institutional review board. The Norway project was approved by the Oslo University institutional review board and regional ethics committee (S-05307). The Sweden study was approved by the Regional Ethical Review Board in Lund, Sweden (registration nos. 2004/762 and 2008/702). All patients provided written informed consent.
: All participants or their surrogate care providers gave written informed consent for publication.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.